Title: Is the Target therapy have a role in the treatment of Metastatic lung cancer in patients who is not fit for chemotherapy? Case Report
Abstract: Introduction: Lung cancer is the most common cause of cancer death worldwide,
with an estimated 1.6 million deaths each year. Approximately 85% of patients
have a group of histological subtypes collectively known as NSCLC, of which lung
adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) are the most
common subtypes.
Epidermal growth factor receptor (EGFR) and its mutations are found to have an
important role in this cancer. Therefore, EGFR tyrosine kinase inhibitors (TKIs) can
work effectively against NSCLC. Gefitinib and Erlotinib, which are a first generation
TKI, and Afatinib, which is a second-generation TKI, are effective as a first-line
therapy for advanced NSCLC.
Case report: We describe here a case of a 52 years old Saudi female nonsmoker
who was diagnosed as a case of adenocarcinoma of lung origin with brain and
inguinal lymph node metastasis. The patient underwent urgent brain surgery,
received palliative radiotherapy and due to his poor general condition, she cannot
received chemotherapy and started on Erlotinb before molecular study results
and fortunately, the patient get excellent clinical response with good radiological
response.
Publication Year: 2018
Publication Date: 2018-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot